Bolt Biotherapeutics (BOLT) Announces Changes to its Board of Directors

Go back to Bolt Biotherapeutics (BOLT) Announces Changes to its Board of Directors

ObsEva SA (OBSV) Announces FDA's Acceptance of New Drug Application for Linzagolix

November 22, 2021 5:46 AM EST

Obseva SA (NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the United States Food and Drug Administration (FDA). The submission is based on data from the two Phase 3 PRIMROSE trials. Linzagolix has a differentiated profile and if approved, would be the first and only GnRH receptor... More

ObsEva SA (OBSV) Appoints Stephanie Brown to its Board

November 22, 2021 5:42 AM EST

ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that Stephanie Brown has been selected to join its Board of Directors and will be proposed for election at the 2022 Annual General Meeting. In the meantime, and effective December 1, 2021, she will join the Board of Directors as an Observer. Ms. Brown brings valuable commercial expertise and industry insight to the Company. Jacky Vonderscher, Ph.D., has decided to step down from the Board effective 19 November... More